These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27978765)

  • 1. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models.
    Degeling K; Koffijberg H; IJzerman MJ
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):17-25. PubMed ID: 27978765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.
    Marshall DA; Grazziotin LR; Regier DA; Wordsworth S; Buchanan J; Phillips K; Ijzerman M
    Value Health; 2020 May; 23(5):566-573. PubMed ID: 32389221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and health economic challenges of personalized medicine].
    Brüggenjürgen B; Kornbluth L; Ferrara JV; Willich SN
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):710-4. PubMed ID: 22526860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.
    Bertier G; Carrot-Zhang J; Ragoussis V; Joly Y
    Genome Med; 2016 Oct; 8(1):108. PubMed ID: 27776531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
    Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
    Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Mammography Screening and Screening Adherence-A Simulation and Economic Evaluation.
    Arnold M; Quante AS
    Value Health; 2018 Jul; 21(7):799-808. PubMed ID: 30005752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalised Healthcare: The DiMA Clinical Model.
    Borro M; Gentile G; Cipolloni L; Foldes-Papp Z; Frati P; Santurro A; Lionetto L; Simmaco M
    Curr Pharm Biotechnol; 2017; 18(3):242-252. PubMed ID: 28183244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer.
    Degeling K; Schivo S; Mehra N; Koffijberg H; Langerak R; de Bono JS; IJzerman MJ
    Value Health; 2017 Dec; 20(10):1411-1419. PubMed ID: 29241901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.
    Doble B; Tan M; Harris A; Lorgelly P
    Expert Rev Mol Diagn; 2015 Feb; 15(2):235-54. PubMed ID: 25142227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ask not what personalized medicine can do for you--ask what you can do for personalized medicine.
    Budin-Ljøsne I; Harris JR
    Public Health Genomics; 2015; 18(3):131-8. PubMed ID: 25766382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system.
    Schleidgen S; Marckmann G
    BMC Med Ethics; 2013 May; 14():20. PubMed ID: 23705623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concepts of 'personalization' in personalized medicine: implications for economic evaluation.
    Rogowski W; Payne K; Schnell-Inderst P; Manca A; Rochau U; Jahn B; Alagoz O; Leidl R; Siebert U
    Pharmacoeconomics; 2015 Jan; 33(1):49-59. PubMed ID: 25249200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Osgood ND; Padula WV; Higashi MK; Wong PK; Pasupathy KS; Crown W
    Value Health; 2015 Jan; 18(1):5-16. PubMed ID: 25595229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized medicine and economic evaluation in oncology: all theory and no practice?
    Garattini L; Curto A; Freemantle N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the clinical implementation of precision medicine companion diagnostics.
    Keeling P; Clark J; Finucane S
    Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Medicine, AI, and the Future of Personalized Health Care.
    Johnson KB; Wei WQ; Weeraratne D; Frisse ME; Misulis K; Rhee K; Zhao J; Snowdon JL
    Clin Transl Sci; 2021 Jan; 14(1):86-93. PubMed ID: 32961010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research.
    Syme R; Carleton B; Leyens L; Richer E
    Public Health Genomics; 2015; 18(6):372-80. PubMed ID: 26565702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges.
    Chen W; Wang Y; Zemlyanska Y; Butani D; Wong NCB; Virabhak S; Matchar DB; Teerawattananon Y
    Value Health; 2023 Sep; 26(9):1425-1434. PubMed ID: 37187236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.